Halozyme Therapeutics | HALO - Operating Expenses


Halozyme Therapeutics reported $192.19M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Amarin USD 51.48M 113K Dec/2025
Amgen USD 4.78B 1.12B Mar/2026
Baxter International USD 6.04B 2.85B Mar/2026
Cara Therapeutics USD 5.94M 983K Sep/2025
Cytokinetics USD 200.58M 4.46M Mar/2026
DBV Technologies USD 37.05M 4.06M Sep/2025
Eli Lilly USD 10.02B 285M Mar/2026
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
Intrexon USD 61.56M 26.1M Jun/2024
Ionis Pharmaceuticals USD 364M 54M Mar/2026
MannKind USD 110.9M 8.74M Mar/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Pfizer USD 90.1B 77.19B Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
United Therapeutics USD 5.9B 5.1B Mar/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025